Mallinckrodt PLC (NYSE:MNK):
The company’s RSI reading has hit 50.70. The stock edged higher by 4.04% to close previous trading session at USD 61.36.
The shares of the company fluctuated in the range of USD 50.90 and USD 132.90 in the course of 52 weeks. Over the three months, the company’s shares have declined by -19.69% and in the past one year, it has lost -52.66%. Additionally, the stock’s year to date performance has declined -17.78%. Over the last five days its shares have surged by 4.07% and in the past six months it has moved down -10.36%.
Further, the company is trading at a price to earnings ratio of 21.49 and the stock is at a price to book ratio of 1.36. The stock’s weekly volatility is calculated as 5.65% and monthly volatility as 7.12% with ATR of 4.07, price to cash ratio of 13.16.
Mallinckrodt PLC (MNK) on March 22, 2016 will report second quarter fiscal 2016 results on Tuesday, May 3, 2016.
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and therapies, in addition to nuclear imaging products. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; analgesics and hemostasis products; and central nervous system drugs. The company’s core strengths include the acquisition and administration of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company’s Specialty Brands segment includes branded medicines; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Nuclear Imaging segment includes nuclear imaging agents.
Sanofi SA (ADR) (NYSE:SNY):
The stock increased by 3.07% to close last trading session at USD 39.94. The company’s shares oscillated in the range of USD 38.95 and USD 40.00 during intraday trade.
A total of 5.80 million shares exchanged hands, above its 3 month average volume of 1.82 million shares. Over the last five days its shares have declined by -0.20% and in the past six months it has moved down -15.90%.
Furthermore, the stock has weekly volatility of 1.67% and monthly volatility of 1.36% with ATR of 0.72. The stock’s RSI is 48.65 and distance from 50-day simple moving average is -0.24%, whereas its distance from 20-day simple moving average is -0.45% and distance from 200-day simple moving average is -13.52%.
Sanofi Pasteur, the vaccines division of Sanofi SA (ADR) (SNY), on March 28, 2016 declared the company’s dengue vaccine, Dengvaxia®, received the award for “The Vaccine Breakthrough of 2016” at the 6th annual Biopharma Industry Awards Event in Singapore.
The Biopharma Industry Awards recognize organizations and individuals for their noteworthy contributions and achievements in Asia’s burgeoning biologics industry, in addition to for their passion to better shape the global biopharmaceutical operation value chain. The award for vaccine breakthrough of the year aims to promote the production of vaccines against prevalent diseases in Asia and recognise vaccines that address a critical medical need in Asia. Criteria for choosing the winner include innovative efforts towards developing novel drugs; efforts dedicated to disease prevention and treatment in Asia; contribution to improving public health outcomes in Asia and partnerships with NGOs and country governments to improve Asia community health programs.